This article is more than 5 years old. Information may no longer be current.

VIDEO: Merck executive highlights ASCO data in lung cancer, Merkel cell carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Alise Reicin, MD, senior vice president and head of global clinical development at Merck KGaA, spoke with HemOnc Today at ASCO Annual Meeting about several studies that spotlighted the efficacy of oncology agents in the company’s pipeline.

Reicin highlighted results of the VISION study, which assessed the selective c-Met inhibitor tepotinib (Merck) for patients with lung cancer whose tumors harbor MET exon 14.

In addition, Reicin spoke about data from M7824 (Merck), a bifunctional TGF-beta and PD-L1 antibody.

The company presented data from two M7824 studies at ASCO. One focused on use of the agent for patients with HPV-positive tumors, and the other assessed use of the agent as second-line treatment for patients with non-small cell lung cancer who had not received prior immunotherapy.

Another ASCO study provided 2-yaer data from a study of the PD-L1 antibody avelumab (Bavencio; Merck KGaA, Darmstadt, Germany, Pfizer) for treatment of Merkel cell carcinoma. Additional data may be available in the next several months from avelumab-treated patients with ovarian cancer and renal cell carcinoma.